1. Home
  2. HKIT vs ELDN Comparison

HKIT vs ELDN Comparison

Compare HKIT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

N/A

Current Price

$2.09

Market Cap

121.6M

Sector

Technology

ML Signal

N/A

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

N/A

Current Price

$1.58

Market Cap

120.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HKIT
ELDN
Founded
1996
2004
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
121.6M
120.8M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
HKIT
ELDN
Price
$2.09
$1.58
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
559.6K
1.7M
Earning Date
04-08-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,812,901.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$1.35
52 Week High
$4.18
$4.98

Technical Indicators

Market Signals
Indicator
HKIT
ELDN
Relative Strength Index (RSI) 58.46 37.48
Support Level $1.42 $1.47
Resistance Level $1.53 $1.75
Average True Range (ATR) 0.24 0.11
MACD 0.07 0.07
Stochastic Oscillator 60.63 42.11

Price Performance

Historical Comparison
HKIT
ELDN

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of businesses such as services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from hardware sales, software sales, IT services, and tax devices and services.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: